ATLANTA – Cybersecurity threats are becoming increasingly prevalent in the med-tech industry. Earlier this month Abbott Laboratories Inc. received an FDA warning letter, citing vulnerabilities with its pacemakers. (See Medical Device Daily, April 17, 2017.) The Abbott Park, Ill.-based company was brought up as an example of the growing threat of cybersecurity breaches during a panel at the Southeastern Medical Device Association's (SEMDA) annual meeting, Wednesday.
Memed Ltd. has received a contract from the Defense Threat Reduction Agency, a branch of the U.S. Department of Defense (DoD) totaling up to $9.2 million. The contract will help fund the Tirat Carmel, Israel-based company's second generation point-of-care platform for distinguishing bacterial from viral infections. Memed began operation in 2009 and has CE mark approval for the Immunoxpert, a first generation in vitro diagnostic blood test to determine whether a patient has either an acute bacterial or viral infection, said Eran Eden, the company's co-founder and CEO. "When we started this journey eight years...
Memed Ltd. has received a contract from the Defense Threat Reduction Agency, a branch of the U.S. Department of Defense (DoD) totaling up to $9.2 million. The contract will help fund the Tirat Carmel, Israel-based company's second generation point-of-care platform for distinguishing bacterial from viral infections.
Becton, Dickinson and Co. (BD) is set to acquire C.R. Bard Inc. for $24 billion in cash-and-stock. The acquisition values Murray Hill, N.J.-based Bard at $317 per share, a 25 percent premium over Friday's close of trading. Bard shareholders could receive $222.93 in cash and 0.5077 shares of Franklin, Lakes N.J.-based BD for each of their shares. The acquisition is expected to close in the fall of this year. Upon news of the pending acquisition, Bard (NYSE:BCR) shares rose more than 19 percent Monday closing at $302.41. BD (NYSE:BDX) shares declined 4.4 percent closing at...
Becton, Dickinson and Co. (BD) is set to acquire C.R. Bard Inc. for $24 billion in cash-and-stock. The acquisition values Murray Hill, N.J.-based Bard at $317 per share, a 25 percent premium over Friday's close of trading. Bard shareholders could receive $222.93 in cash and 0.5077 shares of Franklin, Lakes N.J.-based BD for each of their shares. The acquisition is expected to close in the fall of this year.
Medtronic plc is set to sell its patient care, deep vein thrombosis and nutritional insufficiency businesses within the Patient Monitoring & Recovery (PMR) division of its Minimally Invasive Therapies Group to Dublin, Ohio-based Cardinal Health Inc. for $6.1 billion. The transaction could close sometime by the end of Medtronic's second fiscal quarter in October. Combined, the businesses expected to be divested in the transaction generated about $2.4 billion in revenue over the last four reported quarters. Among the product lines included in the transaction are the company's dental/animal health, chart paper, wound care, incontinence, electrodes,...
Medtronic plc is set to sell its patient care, deep vein thrombosis and nutritional insufficiency businesses within the Patient Monitoring & Recovery (PMR) division of its Minimally Invasive Therapies Group to Dublin, Ohio-based Cardinal Health Inc. for $6.1 billion. The transaction could close sometime by the end of Medtronic's second fiscal quarter in October.
Public genetic databases could have a discrepancy in identifying BRCA1 and BRCA2 variant classifications, which can introduce uncertainty and diminish patient care, according to a study by Myriad Genetics Inc. and researchers from Gradishar from the Feinberg School of Medicine at Northwestern University. The study was published in this month's edition of the journal The Oncologist and results from it show that the Clinvar public database provided discrepant variant classifications more than 26 percent of the time. The Salt Lake City-based company's study evaluated 4,250 BRCA1 and BRCA2 variants. Clinvar is a freely accessible public...
